MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Onconova Therapeutics Company Profile (NASDAQ:ONTX)

Consensus Ratings for Onconova Therapeutics (NASDAQ:ONTX) (?)
Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $36.73 (515.30% upside)

Analysts' Ratings History for Onconova Therapeutics (NASDAQ:ONTX)
Show:
DateFirmActionRatingPrice TargetActions
3/29/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2015Piper JaffrayReiterated RatingOverweight$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/28/2015Janney Montgomery ScottReiterated RatingNeutral -> Fair Value$30.00 -> $15.20View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/3/2015Leerink SwannDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Onconova Therapeutics (NASDAQ:ONTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/12/2016Q1($0.19)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/28/2016Q4($0.27)$0.18ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2015Q3($0.32)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q2($0.56)($0.41)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q1($0.63)($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2015($0.71)($0.62)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.78)($0.69)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014($0.89)($0.77)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014($0.78)($0.87)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2014Q4 13($1.07)($0.68)$1.07 million$1.93 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.66)($1.34)$1.07 million$1.12 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/6/2013Q213($5.21)$0.22 million$0.59 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Onconova Therapeutics (NASDAQ:ONTX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Onconova Therapeutics (NASDAQ:ONTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Onconova Therapeutics (NASDAQ:ONTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/21/2014& Jane Hoffman 2013 De Michaelmajor shareholderBuy143,480$8.47$1,215,275.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Ramesh KumarCEOSell33,543$15.07$505,493.01View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2014Ramesh KumarCEOSell60,000$15.05$903,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2014Michael HoffmanDirectorBuy57,295$11.92$682,956.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/22/2013Michael HoffmanDirectorBuy5,000$14.39$71,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2013E Premkumar ReddyDirectorBuy5,000$12.10$60,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2013& Jane Hoffman 2013 De Michaelmajor shareholderBuy19,700$11.99$236,203.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2013Henry BienenDirectorBuy1,400$12.17$17,038.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2013Ramesh KumarCEOBuy1,100$12.02$13,222.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2013& Jane Hoffman 2013 De MichaelMajor ShareholderBuy1,000,000$15.00$15,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2013Ramesh KumarCEOBuy6,667$15.00$100,005.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2013Thomas J MckearnInsiderBuy3,333$15.00$49,995.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2013Viren MehtaDirectorBuy16,667$15.00$250,005.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/25/2013E Premkumar ReddyDirectorBuy1,000$22.72$22,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Onconova Therapeutics (NASDAQ:ONTX)
DateHeadline
06/21/16 05:12 PMOnconova Therapeutics : Informs Stockholders of Key Dates Related to Announced Rights Offering
06/20/16 07:45 AMOnconova Informs Stockholders of Key Dates Related to Announced Rights Offering - [GlobeNewswire] - NEWTOWN, Pa., June 20, 2016-- Onconova Therapeutics, Inc., a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided an informational ...
06/15/16 10:13 AMOnconova Therapeutics, Inc. (NASDAQ:ONTX) plummeted -11.41%: MTS Systems Corporation (NASDAQ:MTSC ... - KC Register
06/14/16 10:26 AMNetflix (NASDAQ:NFLX) Saws Problems In Numerous Major Asian Markets- Onconova Therapeutics (ONTX ... - Seneca Globe
06/13/16 07:19 AMOnconova Presents Clinical Data from Oral Rigosertib and Azacitidine Combination Study in Higher-Risk Myelodysplastic Syndromes at EHA Annual Meeting - [at noodls] - June 13, 2016 NEWTOWN, Pa., June 13, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products ...
06/06/16 04:39 PMETF’s with exposure to Onconova Therapeutics, Inc. : June 6, 2016 -
06/06/16 04:18 PMOnconova Announces Presentations Highlighting IV Rigosertib and Oral Rigosertib/Azacitidine Combination at 2016 ASCO Annual Meeting - [at noodls] - June 6, 2016 NEWTOWN, Pa., June 06, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products ...
06/02/16 08:36 AMOnconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -
06/01/16 06:05 PMOnconova Files S-1 Registration Statement for Rights Offering to Shareholders - [at noodls] - June 1, 2016 NEWTOWN, Pa., June 01, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) ('Onconova' or the 'Company'), a Phase 3 clinical-stage biopharmaceutical company focused on discovering ...
05/31/16 03:08 PMONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to Ar -
05/31/16 08:02 AMOnconova Announces Upcoming Presentations Related to Advanced Rigosertib Clinical Trials at 2016 ASCO Annual Meeting - [at noodls] - May 31, 2016 NEWTOWN, Pa., May 31, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products ...
05/29/16 06:58 PMPerformance at a Glance on Onconova Therapeutics, Inc. (NASDAQ:ONTX) - HNN - Performance at a Glance on Onconova Therapeutics, Inc. (NASDAQ:ONTX)HNNWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how Onconova Therapeutics, Inc. (NASDAQ:ONTX)'s stock has performed at various points in its past ...and more »
05/23/16 07:04 PMWill This Move At Onconova Therapeutics Inc. (NASDAQ:ONTX) Benefit Shareholders? - Scibility Media - Scibility MediaWill This Move At Onconova Therapeutics Inc. (NASDAQ:ONTX) Benefit Shareholders?Scibility MediaThe move followed a vote that gave the management the green light to perform a 1-for-10 reverse split of Onconova's shares. Because the reverse split will reduce Onconova Therapeutics Inc. (NASDAQ: ONTX)'s outstanding shares, leaving authorized share ...Onconova Therapeutics (ONTX) Adds New DirectorStreetInsider.comStock Highlights: Starbucks Corporation (NASDAQ:SBUX), ENGlobal Corp. (NASDAQ:ENG), Domino's Pizza, Inc ...Benchmark Monitorall 3 news articles »
05/23/16 03:21 PMONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/23/16 12:22 PMOnconova Therapeutics (ONTX) Adds New Director - StreetInsider.com - Scibility MediaOnconova Therapeutics (ONTX) Adds New DirectorStreetInsider.comOnconova Therapeutics, Inc. (Nasdaq: ONTX) announced that Jack E. Stover has been appointed to its Board of Directors. Currently, Mr. Stover serves as Interim President, CEO and Director of Interpace Diagnostics Group Inc., a company that provides ...Will This Move At Onconova Therapeutics Inc. (NASDAQ:ONTX) Benefit Shareholders?Scibility MediaStock Highlights: Starbucks Corporation (NASDAQ:SBUX), ENGlobal Corp. (NASDAQ:ENG), Domino's Pizza, Inc ...Benchmark Monitorall 3 news articles »
05/22/16 07:07 AM8:07 am Onconova Therapeutics announces 1:10 reverse stock split; will take effect at 5:00 PM ET on May 31 -
05/21/16 06:36 PMRevenue Update on Onconova Therapeutics Inc(NASDAQ:ONTX) - Trade Calls - Revenue Update on Onconova Therapeutics Inc(NASDAQ:ONTX)Trade CallsOnconova Therapeutics Inc(NASDAQ:ONTX) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 11, 2016. Company reported revenue of $1.47M. Analysts estimated a revenue of $1.34M. Earnings per ...Onconova Therapeutics Incorporated (NASDAQ:ONTX) Short Interest Increased By 5.59%The Postall 3 news articles »
05/21/16 12:09 AMOnconova Therapeutics, Inc. Announces Results of Annual Meeting, Effective Date of One-For-Ten Reverse Stock Split - NEWTOWN, Pa., May 20, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced results from its 2016 annual ...
05/20/16 07:02 PMWatch List: Asanko Gold (NYSEMKT:AKG), Onconova Therapeutics (NASDAQ:ONTX), Canadian Solar Inc. (NASDAQ ... - KC Register - Watch List: Asanko Gold (NYSEMKT:AKG), Onconova Therapeutics (NASDAQ:ONTX), Canadian Solar Inc. (NASDAQ ...KC RegisterOnconova Therapeutics, Inc. (NASDAQ:ONTX) reported financial results for the first quarter ended March 31, 2016. Total net revenue was $1.5 million for the first quarter of 2016 compared to $0.1 million for the first quarter of 2015. Research and ...and more »
05/20/16 07:02 PMOnconova Therapeutics, Inc. Announces Results of Annual Meeting, Effective Date of One-For-Ten Reverse Stock Split - Nasdaq - Onconova Therapeutics, Inc. Announces Results of Annual Meeting, Effective Date of One-For-Ten Reverse Stock SplitNasdaqNEWTOWN, Pa., May 20, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced results ...Onconova to reverse split stock 1:10 at the end of the month, post-split trading to commence June 1Seeking Alphaall 2 news articles »
05/20/16 07:13 AMOnconova Therapeutics, Inc. Announces Results of Annual Meeting, Effective Date of One-For-Ten Reverse Stock Split - [at noodls] - May 20, 2016 NEWTOWN, Pa., May 20, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products ...
05/13/16 01:14 AMEarnings Report: Onconova Therapeutics Inc (NASDAQ:ONTX) - News Oracle - News OracleEarnings Report: Onconova Therapeutics Inc (NASDAQ:ONTX)News OracleLast Trade: The Company rose 16.71% and finished at $0.560. The daily volume was measured at 1.44 million shares. The 52-week high of the share price is $4.00 and the 52-week low is $0.32. The company has a market cap of $17.54 million. Its latest ...and more »
05/12/16 03:50 PMETF’s with exposure to Onconova Therapeutics, Inc. : May 12, 2016 -
05/11/16 07:59 PMOnconova Therapeutics Inc (ONTX) to Release Earnings on Thursday - Washington News Wire - Washington News WireOnconova Therapeutics Inc (ONTX) to Release Earnings on ThursdayWashington News WireOnconova Therapeutics logo Onconova Therapeutics Inc (NASDAQ:ONTX) is set to release its quarterly earnings data before the market opens on Thursday, May 12th. Analysts expect Onconova Therapeutics to post earnings of ($0.19) per share for the ...Analyst Review: Onconova Therapeutics, Inc. (ONTX)Risers & Fallersall 3 news articles »
05/11/16 04:07 PMOnconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2016 Financial Results - [at noodls] - May 11, 2016 NEWTOWN, Pa., May 11, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products ...
05/05/16 08:35 PMBroker Outlook For Onconova Therapeutics, Inc. (ONTX) - Share Trading News - Broker Outlook For Onconova Therapeutics, Inc. (ONTX)Share Trading NewsThe Company's lead product candidate, rigosertib, is being tested as a single agent and in combination with azacitidine, in clinical trials of patients with myelodysplastic syndromes (MDS) and related cancers. The Company is continuing the Phase II ...Onconova Therapeutics, Inc. (NASDAQ:ONTX) Basic Consolidated EPS At $-1.0564Equities Focusall 2 news articles »
05/02/16 09:12 PMThis Weeks Broker Price Targets For Onconova Therapeutics, Inc. (ONTX) - Share Trading News - This Weeks Broker Price Targets For Onconova Therapeutics, Inc. (ONTX)Share Trading NewsOnconova Therapeutics, Inc. has a 50 day moving average of 0.51 and a 200 day moving average of 0.85. The stock's market capitalization is 11.70M, it has a 52-week low of 0.32 and a 52-week high of 4.00. The share price of the company (ONTX) was up ...and more »
04/29/16 02:16 PMETF’s with exposure to Onconova Therapeutics, Inc. : April 29, 2016 -
04/26/16 07:29 PMBuy Calls For Onconova Therapeutics, Inc. (NASDAQ:ONTX) Stands At 0 - RealistInvestor.com - Buy Calls For Onconova Therapeutics, Inc. (NASDAQ:ONTX) Stands At 0RealistInvestor.comZacks has a rating methodology wherein it gives a 1-5 rating to the stock. As per this methodology, any score of 1 or 2 means a Buy call, a score of 4 or 5 gives sell indication, and a score of 3 implies a recommendation to hold stock. The Buy calls ...and more »
04/26/16 07:29 PMNext Weeks Broker Price Targets For Onconova Therapeutics, Inc. (ONTX) - Share Trading News - Next Weeks Broker Price Targets For Onconova Therapeutics, Inc. (ONTX)Share Trading NewsOnconova Therapeutics, Inc. has a 50 day moving average of 0.50 and a 200 day moving average of 0.89. The stock's market capitalization is 12.90M, it has a 52-week low of 0.32 and a 52-week high of 4.00. The share price of the company (ONTX) was up ...and more »
04/22/16 09:36 PMOnconova Therapeutics (ONTX) Announces Publication of Data on RAS-Targeted Mechanism of Action for Rigosertib - StreetInsider.com - Onconova Therapeutics (ONTX) Announces Publication of Data on RAS-Targeted Mechanism of Action for RigosertibStreetInsider.comOnconova Therapeutics, Inc. (Nasdaq: ONTX) announced that researchers from the Icahn School of Medicine at Mount Sinai, led by Professor E. Premkumar Reddy, scientific founder of Onconova, have published a study describing the novel RAS-targeted ...and more »
04/22/16 09:36 PMOnconova Therapeutics, Inc. (ONTX) Updated Broker Price Targets - Share Trading News - Onconova Therapeutics, Inc. (ONTX) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Onconova Therapeutics, Inc. (ONTX). The latest reports which are currently in issue on Friday 22nd of April state 0 analysts have a rating of “strong buy”, 0 analysts ...Onconova Therapeutics Reports Publication of Positive Study on RAS Mimetic Rigosertib (NASDAQ:ONTX)Sonoran Weekly Reviewall 2 news articles »
04/21/16 06:13 PMOnconova Announces Publication Describing Unique RAS-targeted Mechanism of Action for Rigosertib in the Journal Cell - [at noodls] - April 21, 2016 -- More than 30% of all human cancers driven by RAS, a target previously considered 'undruggable'-- -- Study shows rigosertib inactivates RAS signaling -- NEWTOWN, Pa., April 21, 2016 (GLOBE ...
04/20/16 08:47 PMOnconova Therapeutics (ONTX) Will Present Encouraging Preclinical Data on ARK5 and CDK4 Inhibitor - StreetInsider.com - Onconova Therapeutics (ONTX) Will Present Encouraging Preclinical Data on ARK5 and CDK4 InhibitorStreetInsider.comOnconova Therapeutics, Inc. (Nasdaq: ONTX) announced the presentation of pre-clinical data for its first-in-class dual inhibitor of ARK5 and CDK4/6 at the 2016 AACR Annual Meeting being held April 16-20, 2016 at the Ernest N. Morial Convention Center ...Onconova Therapeutics Presents Pre-Clinical Data on ON 123300 (NASDAQ:ONTX)Sonoran Weekly ReviewLatest Analyst Ratings For Onconova Therapeutics, Inc. (ONTX)Share Trading Newsall 3 news articles »
04/20/16 07:51 AMOnconova Announces Novel Dual Targeting of ARK5 and CDK4/6 by Pre-clinical Compound, ON 123300, in Presentation at 2016 American Association of Cancer Research (AACR) Annual Meeting - [at noodls] - April 20, 2016 NEWTOWN, Pa., April 20, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products ...
04/19/16 09:35 PMBroker Roundup For Onconova Therapeutics, Inc. (ONTX) - Share Trading News - Broker Roundup For Onconova Therapeutics, Inc. (ONTX)Share Trading News10/29/2013 – Onconova Therapeutics, Inc. was upgraded to “buy” by analysts at Citigroup. They now have a USD 27 price target on the stock. The share price of Onconova Therapeutics, Inc. (ONTX) was up +2.15% during the last trading session, with a day ...
04/12/16 08:56 PMAnalyst Review: Onconova Therapeutics, Inc. (ONTX) - Risers & Fallers - Analyst Review: Onconova Therapeutics, Inc. (ONTX)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Onconova Therapeutics, Inc. (ONTX). According to the latest broker reports outstanding on Tuesday 12th of April, 0 analysts have a rating of “strong buy”, 1 analysts ...and more »
04/08/16 09:53 PMRecently Changed Price Targets On Onconova Therapeutics, Inc. (ONTX) - Risers & Fallers - Recently Changed Price Targets On Onconova Therapeutics, Inc. (ONTX)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Onconova Therapeutics, Inc. (ONTX). According to the latest broker reports 0 analysts have a rating of “buy”, 1 analysts “outperform”, 0 analysts “hold”, 0 analysts ...Onconova Therapeutics Incorporated (NASDAQ:ONTX) Sellers Increased By 4.27% Their ShortsStock Callerall 39 news articles »
04/05/16 08:24 PMOnconova Therapeutics, Inc. (NASDAQ:ONTX): Earnings In Focus - Investor Newswire - Onconova Therapeutics, Inc. (NASDAQ:ONTX): Earnings In FocusInvestor NewswireFollowing the recent poll, Onconova Therapeutics, Inc. (NASDAQ:ONTX) can post EPS of $-0.2 in the upcoming results, which can be disclosed anytime around 2016-05-12. The earnings target released by Thomson Reuter's may vary from EPS target of ...and more »
04/04/16 02:37 PMETF’s with exposure to Onconova Therapeutics, Inc. : April 4, 2016 -
04/03/16 07:00 PMOnconova Therapeutics, Inc. (ONTX) Broker Price Targets For The Coming Week - Share Trading News - Onconova Therapeutics, Inc. (ONTX) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Onconova Therapeutics, Inc. (ONTX). The latest reports which are currently in issue on Sunday 3rd of April state 0 analysts have a rating of “strong buy”, 1 analysts ...and more »
04/01/16 10:24 AMOnconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q4, 2015 By the Numbers -
03/31/16 12:04 PMONCONOVA THERAPEUTICS, INC. Financials -
03/30/16 07:30 PMEarnings And Sentiment Revision For Onconova Therapeutics, Inc. (NASDAQ:ONTX) - Investor Newswire - Earnings And Sentiment Revision For Onconova Therapeutics, Inc. (NASDAQ:ONTX)Investor NewswireOnconova Therapeutics, Inc. (NASDAQ:ONTX) has been specified an average broker rating of 1 as collected by Zacks Research. Its rating methodology measures the brokerage firms' estimates on a scale of 1-5. Any score towards the '1-2′ band means a ...and more »
03/30/16 07:30 PMOnconova Therapeutics Inc (ONTX) Receives Buy Rating from HC Wainwright - MicroCap Magazine - MicroCap MagazineOnconova Therapeutics Inc (ONTX) Receives Buy Rating from HC WainwrightMicroCap MagazineOnconova Therapeutics Inc (NASDAQ:ONTX)'s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Tuesday, Market Beat reports. A number of other equities research analysts have also weighed in on ...Onconova Therapeutics Inc (ONTX) Issues Earnings ResultsThe Vista VoiceOnconova Therapeutics Inc (ONTX) Announces Earnings ResultsFinancial Market NewsZacks: Analysts Set $3.50 Target Price for Onconova Therapeutics Inc (NASDAQ:ONTX)South Florida Hedge Fund ManagersWall Street 24 -The Point Reviewall 8 news articles »
03/30/16 07:30 PMOnconova Therapeutics, Inc. (ONTX) Latest Broker Coverage - Risers & Fallers - Onconova Therapeutics, Inc. (ONTX) Latest Broker CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of Onconova Therapeutics, Inc. (ONTX). According to the latest broker reports outstanding on Wednesday 30th of March, 0 analysts have a rating of “strong buy”, 1 ...and more »
03/28/16 06:55 PMOnconova Therapeutics, Inc. (ONTX) Reports Recent Business Highlights and Year-end 2015 Financial Results - ValueWalk - Onconova Therapeutics, Inc. (ONTX) Reports Recent Business Highlights and Year-end 2015 Financial ResultsValueWalkNEWTOWN, Pa., March 28, 2016 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update ...Onconova Therapeutics, Inc. (ONTX) Broker Price Targets For The Coming WeekShare Trading NewsOnconova Therapeutics Reports Narrower FY15 Loss, Revenue Above Single Analyst Estimate (NASDAQ:ONTX)Sonoran Weekly Reviewall 3 news articles »
03/28/16 07:31 AMONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a -
03/28/16 07:11 AMOnconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2015 Financial Results - [at noodls] - March 28, 2016 NEWTOWN, Pa., March 28, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products ...
03/24/16 07:58 PMOnconova Therapeutics Inc (NASDAQ:ONTX), Nature's Sunshine Prod. (NASDAQ:NATR), Neogen Corporation ... - share market updates (press release) - share market updates (press release)Onconova Therapeutics Inc (NASDAQ:ONTX), Nature's Sunshine Prod. (NASDAQ:NATR), Neogen Corporation ...share market updates (press release)Shares of Onconova Therapeutics Inc (NASDAQ:ONTX) ended Wednesday session in green amid volatile trading. The shares closed up +0.090 points or 15.79% at $0.660 with 1.39 million shares getting traded. Post opening the session at $0.55, the shares ...and more »
About Onconova Therapeutics

Onconova Therapeutics logoOnconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways important to cancer cells. It has three clinical-stage product candidates and many preclinical programs that target kinases, cellular metabolism or cell division. The Company's lead product candidate, rigosertib, is being tested as a single agent and in combination with azacitidine, in clinical trials of patients with myelodysplastic syndromes (MDS) and related cancers. The Company is continuing the Phase II portion of a clinical trial of rigosertib oral in combination with azacitidine for patients with MDS and acute myelogenous leukemia (AML).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ONTX
  • CUSIP:
Key Metrics:
  • Previous Close: $5.97
  • 50 Day Moving Average: $5.10
  • 200 Day Moving Average: $5.97
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $16.36M
  • Current Quarter EPS Consensus Estimate: $-7.40 EPS
Additional Links:
Onconova Therapeutics (NASDAQ:ONTX) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha